Impact of Study Design on the Results of Continuation Studies of Antidepressants
Authors:
- Mark ZimmermanMZMark Zimmerman
- Michael A. PosternakMPMichael A. Posternak
- Camilo J. RuggeroCRCamilo J. Ruggero
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (2) , 177-181
Abstract
Antidepressant continuation studies have used 2 different designs. In the placebo substitution design, all patients are initially treated with active medication in an open-label fashion, and then treatment responders are randomized to continue with medication or switch to placebo in a double-blind manner. In the extension design, patients are randomized to a double-blind placebo-controlled acute study at the outset, and responders to active treatment and placebo are continued on the treatment to which they initially responded. We hypothesized that the design of antidepressant continuation studies would impact on the likelihood of relapse. In the extension design, there is no change in treatment. Whether patients responded to placebo or medication, the treatment that produced the response is continued. In contrast, in the placebo substitution design, there is an obvious change in treatment protocol upon initiation of the continuation phase. Patients are aware that they initially received active medication, and there is now a chance that they will be switched to placebo. We speculated that the expectation of a continued positive response is lower in patients treated using the placebo substitution design than the extension design and therefore predicted that relapse rates would be higher. We conducted a meta-analysis of antidepressant continuation studies and compared the relapse rates in continuation studies using these 2 different designs. As predicted, for both the active medication and placebo groups, the frequency of relapse was lower in studies using an extension design. We also found that the difference in relapse risk between antidepressants and placebo was greater with the extension design. Thus, the design of continuation studies of antidepressants was associated with the absolute percentage of patients who relapse on both active medication and placebo, as well as estimates of differential relapse risk between antidepressants and placebo.Keywords
This publication has 21 references indexed in Scilit:
- Relapse Prevention With Gepirone ER in Outpatients With Major DepressionJournal of Clinical Psychopharmacology, 2005
- Extended-release venlafaxine in relapse prevention for patients with major depressive disorderJournal of Psychiatric Research, 2004
- Escitalopram Continuation Treatment Prevents Relapse of Depressive EpisodesThe Journal of Clinical Psychiatry, 2004
- Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic reviewThe Lancet, 2003
- Clinical importance of long-term antidepressant treatmentThe British Journal of Psychiatry, 2001
- The Efficacy and Safety of a New Enteric-Coated Formulation of Fluoxetine Given Once Weekly During the Continuation Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2000
- Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depressionInternational Clinical Psychopharmacology, 1999
- Loss of Antidepressant Efficacy During Maintenance TherapyThe Journal of Clinical Psychiatry, 1998
- Citalopram in doses of 20–60 mg is effective in depression relapse preventionInternational Clinical Psychopharmacology, 1995
- Gepirone in the Treatment of Major DepressionJournal of Clinical Psychopharmacology, 1990